Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
Author(s)
Andrew J. Cutler, MD1, Hemangi R. Panchmatia, MSc2, Alejandro G. Hughes, MPH3, Michael J. Doane, PhD2, Hara E. Oyedeji, CRNP, MS4, Rakesh Jain, MD, MPH5;
1Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA, 2Alkermes, Inc., Waltham, MA, USA, 3Optum, Inc., Eden Prairie, MN, USA, 4Fortitude Behavioral Health, Baltimore, MD, USA, 5Department of Psychiatry, Texas Tech University School of Medicine-Permian Basin, Midland, TX, USA
1Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA, 2Alkermes, Inc., Waltham, MA, USA, 3Optum, Inc., Eden Prairie, MN, USA, 4Fortitude Behavioral Health, Baltimore, MD, USA, 5Department of Psychiatry, Texas Tech University School of Medicine-Permian Basin, Midland, TX, USA
Presentation Documents
OBJECTIVES: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatment was associated with significant reductions in healthcare resource utilization (HCRU) in a previous 6-month pre/post study. This study examined HCRU among patients with schizophrenia in the 12 months after OLZ/SAM initiation.
METHODS: This retrospective analysis used administrative claims data from October 18, 2020, to December 31, 2023, from the Komodo Healthcare Map. Adults with schizophrenia and continuous enrollment ≥12 months before (baseline) and after (follow-up) OLZ/SAM initiation were eligible. Inpatient (IP) admissions, emergency department (ED) and outpatient (OP) visits, and average numbers of inpatient days/patient were compared between baseline and follow-up. A secondary analysis was conducted in patients who received OLZ/SAM treatment for the full 12 months of follow-up.
RESULTS: Patients (n=1287; mean age: 39 years; female: 46%) were on average persistent for 196.6 days. Proportions of patients with ≥1 all-cause, mental health (MH)-related, and schizophrenia-related IP admissions and ED visits significantly decreased between baseline and follow-up (all P<0.001). Mean numbers of all-cause, MH-related, and schizophrenia-related inpatient days/patient decreased significantly (all P<0.001). Proportions of patients with OP visits were similar during baseline and follow-up. Larger reductions in IP admissions and ED visits were observed in the population receiving OLZ/SAM treatment for the entire 12-month follow-up period (both P<0.001; n=481).
CONCLUSIONS: Among patients with schizophrenia, OLZ/SAM initiation may result in clinically meaningful reductions in real-world disease burden, as evidenced by reductions in hospital-based HCRU. Longer treatment retention was associated with improved effectiveness.
This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
METHODS: This retrospective analysis used administrative claims data from October 18, 2020, to December 31, 2023, from the Komodo Healthcare Map. Adults with schizophrenia and continuous enrollment ≥12 months before (baseline) and after (follow-up) OLZ/SAM initiation were eligible. Inpatient (IP) admissions, emergency department (ED) and outpatient (OP) visits, and average numbers of inpatient days/patient were compared between baseline and follow-up. A secondary analysis was conducted in patients who received OLZ/SAM treatment for the full 12 months of follow-up.
RESULTS: Patients (n=1287; mean age: 39 years; female: 46%) were on average persistent for 196.6 days. Proportions of patients with ≥1 all-cause, mental health (MH)-related, and schizophrenia-related IP admissions and ED visits significantly decreased between baseline and follow-up (all P<0.001). Mean numbers of all-cause, MH-related, and schizophrenia-related inpatient days/patient decreased significantly (all P<0.001). Proportions of patients with OP visits were similar during baseline and follow-up. Larger reductions in IP admissions and ED visits were observed in the population receiving OLZ/SAM treatment for the entire 12-month follow-up period (both P<0.001; n=481).
CONCLUSIONS: Among patients with schizophrenia, OLZ/SAM initiation may result in clinically meaningful reductions in real-world disease burden, as evidenced by reductions in hospital-based HCRU. Longer treatment retention was associated with improved effectiveness.
This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD47
Topic
Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Mental Health (including addition)